25.04
-0.27(-1.07%)
Currency In CNY
Address
Building 3, No. 6, Rongjing East Street
Beijing, 100176
China
Phone
86 10 6789 2271
Website
Sector
Healthcare
Industry
Biotechnology
Employees
584
First IPO Date
February 08, 2021
| Name | Title | Pay | Year Born |
| Mr. Chongfei He | Vice President, Secretary to the Board & Chief Financial Officer | 0 | 1969 |
| Mr. Jifeng Shi | Vice President, Chief Research Officer, Core Technical Personnel & Director | 0 | 1974 |
| Mr. Xiang Li | Manager of Information Strategy Research Department & Core Technical Personnel | 0 | 1983 |
| Ms. Xiao Xu | Vice President | 0 | 1974 |
| Ms. Shan Liu | Head of Antibody Drug Development Department & Core Technical Personnel | 0 | 1988 |
| Mr. Zhenqiang Du | Vice President | 0 | 1976 |
| Mr. Lu Yang | Deputy GM of Beiyi Protein Drug R&D and Core Technical Personnel | 0 | 1983 |
| Mr. Jian Tang | Vice President | 0 | 1978 |
| Mr. Desheng Zhou | President & Chairman of the Board | 0 | 1971 |
| Ms. Huan Wang | Executive Vice President & Director | 0 | 1979 |
Beijing Kawin Technology Share-Holding Co., Ltd. engages in the development and production of pharmaceutical products primarily in the areas of liver diseases in China. The company's products include recombinant human interferon alfa-2b injection and compound glycyrrhizin. It provides active pharmaceutical ingredients; clinical research services for biological product development, which include drug substancesfermentation and purification, drug productformulation, and analytical methods development; and contract manufacturing services. The company also serves customers in Pakistan, Colombia, Philippines, Vietnam, Russia, Cambodia, and others. It has strategic partnership with Legend Capital, Haitong Capital, and Cybernaut. The company was founded in 2008 and is based in Beijing, China.
